From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
3-Cl-MCAT Structure.svg
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
  • Illegal in China and Sweden
  • 1-(3-Chlorophenyl)-2-(methylamino)-1-propanone
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass197.66 g·mol−1
3D model (JSmol)
  • CC(NC)C(C1=CC=CC(Cl)=C1)=O
  • InChI=1S/C10H12ClNO/c1-7(12-2)10(13)8-4-3-5-9(11)6-8/h3-7,12H,1-2H3

3-Chloromethcathinone (also known as 3-CMC and clophedrone) is a stimulant drug of the cathinone class that has been sold online as a designer drug, mainly in European countries such as Sweden, Italy and Poland.[1][2] It is closely related in chemical structure to the antidepressant and anti-addictive medication bupropion, which is 3-chloro-N-(t-butyl)cathinone, though the pharmacological profile of 3-CMC is quite different.


As of October 2015 3-CMC is a controlled substance in China.[3] As of April 2019 it is classified as a dangerous and prohibited drug in Sweden.[4]

See also[edit]


  1. ^ Odoardi S, Romolo FS, Strano-Rossi S (August 2016). "A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015". Forensic Science International. 265: 116–20. doi:10.1016/j.forsciint.2016.01.037. PMID 26874736.
  2. ^ Błażewicz A, Bednarek E, Popławska M, et al. (February 2019). "Identification and structural characterization of synthetic cathinones: N-propylcathinone, 2,4-dimethylmethcathinone, 2,4-dimethylethcathinone, 2,4-dimethyl-α-pyrrolidinopropiophenone, 4-bromo-α-pyrrolidinopropiophenone, 1-(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one and 2,4-dimethylisocathinone". Forensic Toxicol. 37 (2): 288–307. doi:10.1007/s11419-018-00463-w.
  3. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  4. ^ Åtta nya ämnen klassas som narkotika, 5 April 2019